The majority of coronary patients are under anti-thrombotic therapy and its interruption may increase cardiovascular risk, while on the other hand, continuation during a surgical procedure may increase the risk of bleeding. This study, which included 1211 patients who underwent non-cardiac surgery, compared the interruption of anti-thrombotic therapy at least 7 days prior vs continuing...
PRAMI: Treating other lesions in addition to the culprit of an acute infarction reduces events.
In the context of an ST-segment elevation myocardial infarction, primary angioplasty to treat the culprit lesion improves the prognosis. The role of angioplasty in unrelated arteries is not well established. Between 2008 and 2013, 465 patients with myocardial infarction underwent primary angioplasty and were randomized to preventive (234 patients) vs non-preventive angioplasty (231 patients). The...
ATOMIC: Omecamtiv Mecarbil does not relieve dyspnea in patients with heart failure
This is a phase 2 randomized, double-blind controlled study to test the effect of omecamtiv mecarbil on progressive doses in patients with dyspnoea and ventricular dysfunction who were admitted for acute exacerbation of heart failure. The primary endpoint of the study was to evaluate the response in dyspnea after a 48-h infusion of omecamtiv mecarbil...
ACCOAST: Pretreatment with prasugrel showed no benefits and increased bleeding in patients with non-ST segment myocardial infarction.
This study evaluated the administration of prasugrel at the time of diagnosis of non-ST segment acute coronary syndrome vs administration at the time of the coronary angiography without indication of angioplasty. 4033 enrolled patients with non-ST segment acute coronary syndrome and positive troponin levels were randomized and who would undergo the angiography between 2 and...
Hokusai-VTE: Endoxaban shows solid results versus warfarin in venous thromboembolism .
The venous thromboembolism is the third most common cardiovascular disease after acute myocardial infarction and stroke . Usual treatment is to use low molecular weight heparin followed by vitamin K antagonists Other studies have shown that the new oral anticoagulants with or without initial heparin are effective alternatives. The endoxaban is a direct Factor Xa...
RE-ALIGN: Dabigatran in mechanical valves. Suspended early due to more bleeding and thrombotic events.
The use of vitamin K antagonists provides excellent protection against thromboembolic complications in patients with mechanical valves, however long-term INR monitoring is needed. Dabigatran is an oral direct thrombin inhibitor which was shown to be effective in patients with atrial fibrillation. Based on these promising results this study was designed to evaluate its use in...
TASTE: Thrombus aspiration in primary angioplasty failed to show benefits at 30 days
The clinical benefit of thrombus aspiration during angioplasty in patients with ST-segment elevation myocardial infarction is uncertain. The purpose of this work was to test if thrombus aspiration reduces mortality. This was a multicenter, prospective, randomized and controlled study that included patients with ST-segment elevation myocardial infarction within 24 hours of evolution. The catheters used...
TAO trial: Otamixaban without advantages as the only anticoagulant in acute coronary syndromes
Despite progress in antiplatelet, anticoagulant therapy and invasive strategy, patients with non-ST-segment elevation acute coronary syndrome present an elevated risk of events. There is no consensus on the use of a single anticoagulant which can be administered in the Coronary Unit and also at the time of coronary intervention. The anticoagulant direct factor Xa inhibitor,...
BIC 8: Copetin associated with troponin can rule out acute myocardial infarction in the emergency room.
The acute chest pain is responsible for more than 11 % of queries to an emergency service . Only 10% of these patients really have an acute myocardial infarction. The standard protocol for managing these patients includes serial electrocardiogram, dosage of biomarkers and an observation time of 6-12 hours. This overloads the emergency services and...
AQUARIUS: Aliskiren, without impact on the progression of atherosclerosis
This double-blind, multicenter randomized study compared aliskiren versus placebo in 613 patients with coronary artery disease and systolic blood pressure between 125 and 139 mm Hg (pre hypertensive stage) together with 2 risk factors. All patients underwent coronary intravascular ultrasonography (IVUS) and randomized to aliskiren 300 mg (305 patients) or placebo (308 patients). At 72...